-
Five Star Stock Watch: Sarepta Therapeutics
Tuesday, April 22, 2014 - 12:54pm | 455Read More...After trending lower for the last couple of months, Sarepta Therapeutics surged 39.3 percent after announcing plans to file for a new drug application (NDA) for their lead drug eteplirsen later this year. You see, Sarepta had been told last year by the Food and Drug Administration (FDA) that...
-
Market Wrap For January 6: Busy Day For Analysts Upgrades and Downgrades
Monday, January 6, 2014 - 5:58pm | 2261Read More...Monday's trading session featured a plethora of analyst upgrades and downgrades. With little key economic data released, markets were relatively tame as major indices failing to meaningfully move in any one direction. The Senate appears to be set to officially Janet Yellen to lead the Federal...
-
Edison Investment Research Believes FDA Approval for Sarepta's Eteplirsen Could Come Before Year-End
Wednesday, April 24, 2013 - 11:56am | 161Read More...In a report published Wednesday, Edison Investment Research analyst Jason Zhang, Ph.D. commented on Sarepta Therapeutics' (NASDAQ: SRPT) recent reaction to the FDA's request for additional information on eteplirsen. In the report, Zhang wrote, "The FDA's request for additional information from the...
